Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Confident Cosentyx Can Keep Competition At Bay

Sales Expected To Grow Beyond $5bn

Executive Summary

The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.

You may also be interested in...



UCB Is RADIANT As Bimekizumab Beats Cosentyx For Psoriasis

The psoriasis market is crowded and fiercely competitive but the Belgian group's bimekizumab has bested Novartis's interleukin-17A behemoth Cosentyx in a head-to-head study. Whether UCB goes it alone or signs up a large partner with a large marketing budget remains to be seen.

Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis

Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.

Can UCB's Bimekizumab Go From Last To First In Psoriasis?

Although it is playing catching up on well-established rivals, especially Novartis's Cosentyx, the Belgian company believes that bimekizumab provides both a fast and durable response for psoriasis patients, driven by impressive PASI 100 rates.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel